secwatch.observer — SEC 8-K summary
======================================

Issuer:     SeaStar Medical Holding Corp (ICU)
CIK:        0001831868
Form:       8-K
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0000950170-24-126487
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SeaStar Medical reports Q3 revenue of $67,500 from first commercial sales of QUELIMMUNE; net loss narrows to $4.5M
--------------------------------------------------------------------------------

- First commercial revenue of $67,500 from direct QUELIMMUNE shipments to hospital customer; no revenue in Q3 2023.
- Net loss $4.5M ($1.10/share) vs $7.2M ($9.02/share) in Q3 2023; cash $2.1M as of Sep 30.
- Eliminated all $9M+ long-term debt during 2024; no long-term debt outstanding.
- FDA granted Breakthrough Device Designation for SCD in chronic dialysis (4th designation).
- NEUTRALIZE-AKI adult trial: 59 subjects enrolled, record October enrollment; 12 clinical sites.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831868/000095017024126487/0000950170-24-126487-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831868/000095017024126487/icu-20241113.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-126487

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer